Novel Virus Brings Novel Threats To Global Pharmaceutical Manufacturing
As coronavirus spreads into China’s manufacturing region, quarantines and travel restrictions challenge international flow of pharmaceuticals, ingredients and personnel.
You may also be interested in...
US agency ensures pharmaceutical companies could manufacture critical medicines domestically even if cut off from China's API suppliers, while stockpiling pandemic medicines during pandemic with Baxter, Fresenius contracts.
Coronavirus hysteria sweeps up languishing drug shortage legislation; prospects for new reporting and risk management planning requirements improve.
As virus impedes China’s API production and spreads to other global manufacturing centers, need for robust supply chain alternatives becomes clear.